IBI3042, an oral medicine, in healthy adults and adults with overweight or obesity

Trial details

Who runs it

Innovent Biologics (Suzhou) Co. Ltd.

Trial code

NCT07793019

Record updated

11 September 2026

Original description

This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in adults with overweight or obesity. The main goal is to assess the safety and tolerability of IBI3042. The study will also evaluate how IBI3042 is processed in the body and explore its effects on body weight and other metabolic measures. Some participants will receive placebo, and some Part B groups will also receive orforglipron for comparison.Read full original descriptionShow less

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Single-Dose IBI3042 in Healthy Participants and Multiple-Dose IBI3042 in Overweight or Obese Participants

This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in adults with overweight or obesity. The main goal is to assess the safety and tolerability of IBI3042. The study will also evaluate how IBI3042 is processed in the body and explore its effects on body weight and other metabolic measures. Some participants will receive placebo, and some Part B groups will also receive orforglipron for comparison.

Inclusion: Aged 18 to 55 years, inclusive; For Part A: BMI ≥20 and <30 kg/m\^2 and body weight ≥50 kg; For Part B: BMI ≥24 and ≤40 kg/m\^2, with stable body weight during the 3 months prior to screening; Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use highly effective contraception during the study and for 90 days after the last dose; Able and willing to comply with study procedures and voluntarily provide written informed consent.

Exclusion: Use of medications that may significantly affect gastrointestinal motility, appetite, or drug absorption within 3 months prior to screening; Use of prescription or over-the-counter medications, dietary supplements, or herbal medicines within 2 weeks or 5 half-lives prior to screening, except as permitted by the protocol; Participation in another drug or medical device clinical study within 3 months prior to screening or within 5 half-lives of the investigational drug, as applicable; Known or suspected hypersensitivity to any component of the study drug or to GLP-1 receptor agonists; History of diabetes or abnormal glycemic parameters at screening; Personal or family history of thyroid C-cell carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2A or 2B), or calcitonin ≥20 ng/L at screening; History of acute or chronic pancreatitis, or clinically significant pancreatic enzyme elevation at screening; Clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease that may increase study-related risk or interfere with study assessments; History of malignancy within 5 years, except for basal cell or squamous cell skin cancer; Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in the study; Clinically significant abnormalities in physical examination or laboratory tests at screening.

ClinicalTrials.gov NCT07793019